Hypertension is a heart-related disease which results in elevated
blood pressure in the arteries. It is also known as arterial
hypertension or high blood pressure. This disease occurs on account of
alcohol, smoking, obesity, and other genetic factors. Although, the
disease can be treated with a healthy diet and exercise,
antihypertensives are recommended to control it.
Antihypertensives are a class of drugs which can prevent hypertension
and other cardiovascular-related disorders like strokes and myocardial
infarction. They are likely to reduce the heart conditions by 21%. Beta
blockers, thiazide diuretics, ACE inhibitors, calcium channel blockers,
and angiotensin II receptor antagonists (ARBs) are the different types
of antihypertensive therapeutics in major developed markets.
Browse Detail Report With TOC @ http://www.hexareports.com/report/antihypertensive-therapeutics-in-major-developed-markets/details
Thiazide diuretics aid in reducing salt and water from the kidneys.
They are the first drugs to be administered for a patient undergoing
hypertension treatment. ACE inhibitors reduce serum creatinine levels
better than beta blockers. They are considered the first line of defense
against heart-related disorders. ARBs reduces the risko f myocardial
infarction when combined with amlodipine. Beta blockers are considered
risky and can lead to strokes or type-2 diabetes. However, they prevent
heart attacks in persons who have already experienced a heart attack.
The hypertension market was estimated to have earned USD 40 billion
of revenue in 2013. The market will attain USD 37 billion by 2020, owing
to the patent expiry of major drugs. It is predicted to grow at a 2.6%
CAGR during the period of 2014 to 2017. The market will experience
growth on account of fixed-dose combination (FDCs) drugs, the rising
geriatric population, and a low diagnosis rate.
Request A Sample copy of This Report @ http://www.hexareports.com/sample/104209
FDCs include Amturnide, Azor, Twynsta, Exforge Tribenzor, Valturna,
Benicar HCT, Tekturna HCT, Tekamlo, and Edarbyclor. New drugs in the
pipeline are AHU377 + valsartan and azilsartan + amlodipine. Patients
undergoing the treatment were known to have reduced levels of blood
pressure. Drugs about to lose their patent are Exforge in 2014, Cozaar
in 2010, Tekturna and Tekturna HCT in 2018, Benicar in 2016, and Atacand
and Avapro in 2012.
The hypertension market has evolved from creating drugs to providing
step-by-step special treatment dependent on the seriousness of the
disease. The new classes of antihypertensive drugs are able to protect
the kidneys, liver, heart, and brain from internal damage.
About Us:
Hexa Reports is a market research and consulting organization,
offering industry reports, custom research and consulting services to a
host of key industries across the globe. We offer comprehensive business
intelligence in the form of industry reports which help our clients
obtain clarity about their business environment and enable them to
undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Felton Office Plaza,
Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
1-800-489-3075
Email Us: sales@hexareports.com
Website: http://www.hexareports.com/
Visit our Blog: http://hexareports.blogspot.com/
No comments:
Post a Comment